Frost & Sullivan Commends Paras Biopharmaceuticals’ Comprehensive Technologies and Biologics Portfolio that Economically and Efficiently Addresses Global Affordable Healthcare Issues

— The company leverages its keen understanding of protein purification to achieve the highest purification standards and product quality

LONDON, Dec. 11, 2014 /PRNewswire/ — Based on its recent analysis of the biopharmaceuticals industry, Frost & Sullivan recognizes Paras Biopharmaceuticals with the 2014 Europe Frost & Sullivan Award for Technology Innovation Leadership. Belying its status as a relatively fledgling biopharmaceutical, Paras Biopharmaceuticals has built a robust portfolio of proprietary technologies for the high-level expression of biosimilars and long therapeutic peptides in specially designed, genetically stable clones. The company strives to offer innovative solutions for the effective and economic production of recombinant therapeutics.

Paras Biopharmaceuticals has developed three main technologies. The first is Diabrid® Technology, which works as a critical enabler for achieving the right target product. The second, NobleCleav® Technology, facilitates high-level production of authentic biologics by combining specificity and activity of processing of recombinant therapeutic peptides and therapeutic proteins. Lastly, the Biomultifold® Microbial High Expression technology helps achieve expression levels of multigrams of therapeutic proteins per litre of fermentation using E. coli.

Best suited for robust scale-up and commercial production, the Biomultifold® and Diabrid® technologies are applicable in a wide range of biopharmaceuticals, including the production of monoclonal antibody fragments in E. coli.

"Paras Biopharmaceuticals has developed proprietary expression vectors based on the most optimum genetic codes selected for each amino acid of the therapeutic product. A selective combination is then developed using the most advanced optimization programs available to achieve the highest levels of protein expression," said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. "Genes are coupled with suitable Diabrid® partners to achieve a unique combination of therapeutic proteins and peptides."

Currently, Paras Biopharmaceuticals is developing several biopharma active pharmaceutical ingredients (APIs) based on its proprietary manufacturing technologies, targeting therapeutic areas such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes), and oncology. It offers a comprehensive technology package for the production of APIs of biosimilars, including proprietary designed robust production clones, reports on cloning, cell line development techniques, media optimization, product optimization, purification development, and product API characterization.

"The company not only possesses exceptional process development skills to achieve the highest levels of production, but also has extensive experience in handling different kinds of chromatography columns and the most advanced column packaging systems," noted Chidambaram. "Its core strengths, ranging from media selection and development, optimization of process parameters, screening of resins to minimizing aggregation concepts in purification have earned the company a reputation for being an important innovator in biopharmaceuticals."

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry and the positive impact on brand perception. "Paras Biopharmaceuticals are grateful to receive this award as it recognises the commitment and hard work of the Paras team," said Paras Biopharmaceuticals’ Director of Global Strategic Alliance Dr. Hans Soderlund.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Paras Biopharmaceuticals

Paras Biopharmaceuticals Finland Oy is an acclaimed enabler of biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Paras GMP facilities in Finland are dedicated to the development, scale-up and GMP production of recombinant products. Paras offer optimized scale-up technologies and products for clinical and commercial manufacturing.

Paras’ work revolves around two main streams

  • Biosimilars comprised of osteoporosis recombinant Teriparatide, analog insulin and therapeutic fragment of monoclonal antibodies
  • High value recombinant enzymes such as Enterokinase (and other enzymes in pipeline).

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion 

Join Us:           Join our community 

Subscribe:       Newsletter on "the next big thing" 

Register:         Gain access to visionary innovation 


Melanie Parkinson
Best Practices, Frost & Sullivan
P: +44 (0) 207 915 7867
T: @MelanieFrostBPA 

Dr Mark Jackson Ph.D. MPhys (Hons)
Research & Administrative Associate, Biologics and Biosimilars Technology Group
P: +358 (0) 442709462

Leave a Reply